Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial

Affiliations

¹ Interdisciplinary Tumor Center Mannheim, University Hospital Mannheim, University Heidelberg, 68167 Mannheim, Germany. Electronic address: Ralf-Dieter.Hofheinz@medma.uni-heidelberg.de.
² Division of Hematology, Oncology and Tumor Immunology, Medical Department, Charité University Hospital Berlin, Berlin, Germany.

Comment

Ralf-Dieter Hofheinz et al. Lancet Oncol. 2019 Aug.

. 2019 Aug;20(8):1036-1037.

doi: 10.1016/S1470-2045(19)30390-0. Epub 2019 Jun 28.

¹ Interdisciplinary Tumor Center Mannheim, University Hospital Mannheim, University Heidelberg, 68167 Mannheim, Germany. Electronic address: Ralf-Dieter.Hofheinz@medma.uni-heidelberg.de.
² Division of Hematology, Oncology and Tumor Immunology, Medical Department, Charité University Hospital Berlin, Berlin, Germany.

No abstract available

Comment on

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Bekaii-Saab TS, et al. Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28. Lancet Oncol. 2019. PMID: 31262657 Free PMC article. Clinical Trial.